These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1523 related items for PubMed ID: 12750695
1. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D, Chronic Leukemia Working Party of the EBMT. Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695 [Abstract] [Full Text] [Related]
3. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W, Cooperative German Transplant Study Group. J Clin Oncol; 2003 Jul 15; 21(14):2747-53. PubMed ID: 12860954 [Abstract] [Full Text] [Related]
4. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W. Haematologica; 2002 Jan 15; 87(1):52-8. PubMed ID: 11801465 [Abstract] [Full Text] [Related]
5. Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. O'Meara A, Halter J, Heim D, Gerull S, Bucher C, Passweg J, Buser A, Stern M. Biol Blood Marrow Transplant; 2013 Jan 15; 19(1):82-6. PubMed ID: 22897965 [Abstract] [Full Text] [Related]
6. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group. Ann Hematol; 2003 Jun 15; 82(6):336-42. PubMed ID: 12728337 [Abstract] [Full Text] [Related]
17. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK, Hochhaus A, Niederwieser D, Sayer HG. J Cancer Res Clin Oncol; 2016 Jan 01; 142(1):317-24. PubMed ID: 26424692 [Abstract] [Full Text] [Related]